BCR and diffuse large B-cell lymphoma: Aberrant activation of the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway is observed in a significant subset of DLBCL samples and is driven by chronic activated B-cell receptor (BCR) signaling or the loss of phosphatase and tensin homolog (PTEN) expression [10–13].